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Received July 21, 2014; accepted November 14, 2014AbstractBackground: Glaucoma is a leading cause of irreversible blindness worldwide. It is characterized by progressive deterioration of the visual field
(VF) that results in a complete loss of vision. This study aimed to determine the risk factors associated with VF progression in Chinese patients
with primary open-angle glaucoma (POAG).
Methods: We reviewed the charts of POAG patients who visited our clinic between July 2009 and June 2010. We included patients with five or
more reliable VF tests using the Humphrey Field Analyzer (Humphrey Instruments, San Leandro, CA, USA) during a period of at least 2 years.
The scoring system of the Collaborative Initial Glaucoma Treatment Study (CIGTS) was used to code the VF. Progression was defined as an
increasing score 3, compared to the averaged baseline data. Univariate and multivariate logistic regression analyses were performed to identify
the risk factors of VF progression.
Results: There were 92 patients (representing 92 eyes) with an average of 8.9 reliable VFs over a mean follow up of 5.4 years. Multivariate
logistic regression showed that eyes with more VF tests [odds ratio (OR) ¼ 1.500, p < 0.010] and either increased peak intraocular pressure
(IOP) (OR ¼ 1.235, p ¼ 0.044) or a wide IOP range (OR ¼ 1.165, p ¼ 0.041) favored VF progression. High myopia (less than 6.0 D) was not a
risk factor (OR ¼ 1.289, p ¼ 0.698) for VF progression in this study.
Conclusion: In addition to a greater number of VF tests, Chinese patients with treated POAG who experienced a high peak IOP or a wide range
of IOP during follow up were more likely to have VF deterioration.
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Primary open-angle glaucoma (POAG) is a leading cause of
blindness worldwide.1 Despite the growing understanding of
its pathophysiology and advances in the management arma-
mentarium against glaucoma, the challenges of predicting and
halting disease progression remain. The percentage of visual
field (VF) progression in open-angle glaucoma have ranged
from 12% to 76% in investigations with different studyociation. All rights reserved.
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Candidate factors associated with glaucoma progression
include old age,2e4,6,8 worse baseline mean deviation (MD),4,6
increased baseline intraocular pressure (IOP), increased mean
IOP, increased peak IOP, greater IOP fluctuation during the
follow-up period,2,3,6e10 the presence of disc hemorrhage,2,6,9
increased number of VF tests,8 and myopia.11,12 However,
results regarding the role of myopiada common refractive
error and ocular disease in Chinese peopledare inconsistent
across studies. Debate exists over which IOP-related variable
is more closely related to disease progression in treated pa-
tients with POAG.
Some studies such as the Advanced Glaucoma Intervention
Study (AGIS) show a positive correlation between visit-to-
visit IOP fluctuation and VF progression.3,8,13e15 However,
De Moraes et al9 suggest that the peak IOP rather than IOP
fluctuation is a predictor of progression. The latter study is
supported by one glaucoma animal study that demonstrated a
more predictive role of maximum IOP in structural change,
compared to the mean IOP and IOP variability.16 The role that
myopia has in the disease course of POAG similarly remains
to be clarified because of its clinical significance and high
prevalence in Taiwan. Some studies report that high myopia
has an impact on VF exacerbation,11,12 whereas other studies
have found no such correlation.3,17,18
Patients with different ethnic backgrounds show variations
in the rate of VF deterioration4; therefore, they may also differ
in the risk factors associated with VF progression. In light of
limited data on risk factors for glaucomatous VF progression
in Chinese people, we conducted this retrospective study to
evaluate the rate of VF progression and determine the asso-
ciated risk factors in a cohort of Chinese patients with POAG.
2. Methods
We reviewed the medical records of all POAG patients who
had regular follow up at our glaucoma service for at least 2
years and maintained their follow-up schedules during the
study period between July 2009 and June 2010. The study
protocol was approved by the Institutional Review Board of
the Taipei Veterans General Hospital (Taipei, Taiwan). The
requirement for informed consent was waived (2013-08-
010AC).
The diagnosis of POAG was based on normal open angles,
glaucomatous optic nerve head changes, and reproducible VF
defects of the retinal nerve fiber bundle pattern in at least two
consecutive reliable field tests. The Glaucoma Hemifield Test
and the pattern standard deviation of VF reports should
correspond to outside normal limits and correspond to <5% of
the age-matched normal patients, respectively. Patients with a
pretreatment IOP 22 mmHg were classified as having high-
tension POAG (HTG), and patients with a pretreatment IOP
<22 mmHg at three or more visits were regarded as having
normal-tension glaucoma (NTG). Patients with secondary
glaucoma associated with corticosteroid use, trauma, ocular
inflammation, or pigment dispersion were excluded. Also
excluded were eyes with a patent iridotomy, with a bestcorrected visual acuity (BCVA) worse than 6/20, or with
concomitant ocular disease such as diabetic retinopathy, age-
related maculopathy, or neurological diseases that influence
VF presentation. Eyes that received cataract extraction or
glaucoma surgical intervention during the follow-up period
were documented for surgical type and date of intervention.2.1. VF testsWe retrieved VF tests that were performed using program
24-2 of a Humphrey Field Analyzer 750 (Humphrey In-
struments, San Leandro, CA, USA) with the Swedish Inter-
active Thresholding Algorithm standard. The VF results
included in the analysis had to fulfill the reliability criteria that
the fixation loss, false-positive results, and false-negative re-
sults were all <33%. After excluding the VF tests with
inconsistent patterns that reflected a learning effect, the first
two reliable consecutive field tests were treated as the baseline
fields.
Each VF was then scored, based on the Collaborative Initial
Glaucoma Treatment Study (CIGTS) scoring system.19 In
brief, each point with a total deviation probability plot value of
5% was considered a depressed location. A weight was
administered to each depressed location, depending on the
minimum depth of defects among a given point and the
neighboring two most defective points. Minimum defects of
0.05, 0.02, 0.01, and 0.005 were administered weights of 1, 2,
3, and 4, respectively. Locations without a probability plot
value <0.05 in the two most depressed neighboring locations
were given a score of zero. The weight of all 52 points were
summed (ranging from 0 to 208), then the sum was scaled
(divided by 10.4) to range from 0 (no defect) to 20 (all points
show a defect at the p < 0.005 level). Eyes with a baseline
CIGTS score of 18 were excluded from the study. Only eyes
that had at least five qualified VF tests over a minimum span
of 2 years were included in the analysis. If both eyes of one
patient fulfilled the inclusion criteria, the eye with a lower
CIGTS score was selected for the final analysis.2.2. Definition of VF progressionProgression was defined as an increasing CIGTS score of
3, compared to the average score of the two baseline fields,
and confirmed by two additional tests.202.3. Statistical analysisStatistical analyses were performed using statistical soft-
ware (SPSS, version 17.0; SPSS, Inc., Chicago, IL). A p value
< 0.05 was considered statistically significant. Because of the
inclusion of 92 patients (13 progressors and 79 non-
progressors), the study had 80% of power to detect an OR of
0.4 or 2.5 for progression per one standard deviation change in
the covariate (a ¼ 0.05).
Age, sex, and variables with p < 0.2 in univariate logistic
regression analysis were entered stepwise into the multivariate
logistic regression analysis. The mean IOP was also
Table 1
Baseline and follow-up data of all patients.
All (n ¼ 92) HTG (n ¼ 47) NTG (n ¼ 45) p
Baseline
Age (y) 57.98 ± 15.54 55.62 ± 17.13 60.44 ± 13.43 0.240
Female, n (%) 26 (28) 16 (34) 10 (22)
BCVA 0.83 ± 0.20 0.83 ± 0.21 0.83 ± 0.19 0.946
Spherical
equivalent (D)
3.10 ± 4.40 4.02 ± 4.51 2.18 ± 4.14 0.058
Axial length
(mm)
25.07 ± 1.78 25.26 ± 1.83 24.85 ± 1.72 0.313
IOP (mmHg) 20.71 ± 3.98 23.54 ± 3.18 17.36 ± 1.23 <0.001*
CCT (mm) 553 ± 30 562 ± 31 544 ± 25 0.003*
No. of glaucoma
medications
1.31 ± 0.60 1.49 ± 0.74 1.12 ± 0.33 0.022*
Mean
deviation (dB)
8.87 ± 5.93 9.08 ± 6.21 8.66 ± 5.68 0.916
PSD (dB) 7.56 ± 3.94 7.55 ± 4.15 7.58 ± 3.74 0.888
Disc hemorrhage,
n (%)
6 (7) 3 (6) 3 (7)
Glaucoma family
history, n (%)
14 (15) 7 (15) 7 (16)
Hypertension,
n (%)
24 (26) 8 (17) 16 (38)
Cardiovascular
disease, n (%)
19 (21) 5 (11) 14 (31)
Diabetes
mellitus, n (%)
15 (16) 7 (15) 8 (18)
Follow up
IOP (mmHg)
Mean 14.54 ± 2.59 15.87 ± 2.58 13.15 ± 1.74 <0.001*
Fluctuation 2.14 ± 0.92 2.36 ± 1.04 1.91 ± 0.70 0.023*
Range 8.41 ± 4.50 9.48 ± 5.57 7.30 ± 2.65 0.129
Peak 19.29 ± 4.44 21.4 ± 5.01 17.1 ± 2.24 <0.001*
Period (y) 5.41 ± 2.3 5.05 ± 2.32 5.80 ± 2.23 0.097
Qualified VF
tests
per person
8.85 ± 3.52 7.64 ± 2.52 10.11 ± 3.97 0.002*
Surgical
intervention,
n (%)
20 (22) 12 (26) 8 (18)
Progressor, n (%) 13 (14) 7 (15) 6 (13)
Continuous variables are presented as the mean ± the standard deviation.
* Indicates statistical significance.
BCVA ¼ best corrected visual acuity; CCT ¼ central corneal thickness;
HTG ¼ high-tension glaucoma; IOP ¼ intraocular pressure; NTG ¼ normal-
tension glaucoma; PSD ¼ pattern standard deviation; VF ¼ visual field.
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repeatedly been associated with disease progression. Factors
taken into account included demographic data, ocular pa-
rameters, and medical conditions. The IOP data were included
from the first baseline VF result. The IOP within 1 month after
glaucoma surgery or within 1 week after bleb revision were
omitted. The standard deviation (SD) of the IOP readings from
all other visits throughout the follow-up period was regarded
as the long-term IOP fluctuation, whereas the range of IOP
was the difference between the highest (i.e., peak) and the
lowest IOP readings from visit to visit.
3. Results
Based on our inclusion and exclusion criteria, we included
96 patients (representing 96 eyes) for chart review. Ninety-two
patients (representing 92 eyes) were included for final anal-
ysis, which included 45 NTG and 47 HTG patients. Table 1
lists the clinical characteristics. There were significant differ-
ences in the distribution of central corneal thickness, various
IOP-related parameters, and the number of VF tests between
NTG and HTG, although the slope of the VF mean deviation
and CIGTS score over time were comparable between the two
groups. Therefore, the data from the NTG and HTG patients
were grouped together as open-angle glaucoma for further
analysis.
In all, 8.85 reliable fields were available for each patient
after a mean follow up of 5.4 years. The average MD declined
from 8.87 dB to 9.52 dB ( p ¼ 0.130), the mean pattern SD
increased from 7.56 dB to 8.14 dB ( p ¼ 0.030), and the
CIGTS score increased from 9.86 to 10.08 ( p ¼ 0.630)
throughout the follow-up period. Thirteen eyes of 13 patients
(14%) showed VF progression during the follow-up period.
In univariate logistic regression analyses, we found the
following were associated with VF progression: disc hemor-
rhage, glaucoma family history, visit-to-visit IOP fluctuation,
duration of follow-up period, range of IOP and peak IOP
during follow up, and number of VF tests ( p < 0.2; Table 2).
Owing to high correlations among three IOP parameters with
p < 0.2 in univariate analysis (IOP fluctuation vs. range of IOP,
r ¼ 0.94, p < 0.001; range of IOP vs. peak IOP, r ¼ 0.82,
p < 0.001; and peak IOP vs. IOP fluctuation, r ¼ 0.76,
p < 0.001), different models that included only one of these
variables were established. Model 1 showed that eyes with a
greater IOP range and more VF tests during follow up were
more likely to be progressors, after adjusting for age, sex, disc
hemorrhage, mean IOP, family history of glaucoma, and
follow-up period (Table 3), and Model 2 showed that eyes with
an increased peak IOP and more VF tests during the follow-up
period were more likely to progress (Table 4). The results
remained similar after excluding the data of patients (n ¼ 8)
who had received cataract surgery during the follow-up period.
Univariate logistic regression analysis did not identify high
myopia (i.e., a spherical equivalent of 6.0 D or less) as a
potential risk factor for disease progression (OR ¼ 1.289,
p ¼ 0.698). In addition, by estimating the slope of the VF
mean deviation or the CIGTS score, we did not find acorrelation between the VF change and axial length or
spherical equivalent by linear regression analysis.
4. Discussion
The aim of glaucoma treatment is to maintain the quality of
life by preserving patients' visual function througout their
lifetime. Because VF loss has substantially negative impacts
on visual function in glaucoma patients,21 the detection of VF
progression is important in disease management and thera-
peutic decisions. To date, no gold standard has been estab-
lished to define clinically relevant VF progression, but the
consensus is to use event-based methods in the first few years
of follow up when few VFs are available for an authentic trend
analysis.
Table 2
Univariate logistic regression analysis of risk factors for glaucoma progression
(n ¼ 92).
Odds
ratio
beta
value
SE p 95% confidence
interval
Baseline
Age (y) 0.995 0.005 0.019 0.791 0.958e1.033
Female 1.152 0.141 0.651 0.828 0.321e4.127
NTG 0.879 0.129 0.600 0.830 0.271e2.850
BCVA 7.720 2.044 1.840 0.267 0.210e284.1
Spherical
equivalent (D)
0.993 0.007 0.068 0.923 0.869e1.135
Axial length (mm) 1.096 0.091 0.182 0.616 0.767e1.565
IOP (mmHg) 3.002 1.099 0.968 0.256 0.450e20.03
CCT (mm) 1.001 0.001 0.010 0.919 0.981e1.021
Glaucoma
medication
1.691 0.525 0.492 0.286 0.644e4.440
Mean
deviation (dB)
1.053 0.052 0.058 0.374 0.940e1.180
PSD (dB) 0.991 0.009 0.077 0.902 0.852e1.152
Disc hemorrhage 3.409 1.226 0.924 0.185 * 0.557e20.86
Glaucoma
family history
3.067 1.121 0.690 0.104 * 0.794e11.84
Hypertension 0.829 0.188 0.706 0.790 0.208e3.305
Cardiovascular
disease
1.896 0.640 0.666 0.337 0.514e6.994
Diabetes mellitus 0.387 0.950 1.082 0.380 0.046e3.224
Follow up
IOP (mmHg)
Mean 1.005 0.005 0.116 0.966 0.800e1.262
Fluctuation 1.673 0.515 0.283 0.069 * 0.962e2.912
Range 1.137 0.128 0.058 0.027 * 1.015e1.274
Peak 1.085 0.082 0.061 0.181 * 0.963e1.224
Period (y) 1.195 0.179 0.134 0.183 * 0.919e1.554
Number of
VF tests
1.303 0.264 0.083 0.001 * 1.108e1.531
* This value ( p < 0.2) was entered into multivariate logistic regression
analysis.
BCVA ¼ best corrected visual acuity; CCT ¼ central corneal thickness;
IOP ¼ intraocular pressure; NTG ¼ normal-tension glaucoma; PSD ¼ pattern
standard deviation; SE ¼ standard error; VF ¼ visual field.
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define VF progression because it has good specificity and the
best sustainability, compared to other proposed criteria such as
the Early Manifest Glaucoma Trial (EMGT) criteria and the
AGIS score.22 We detected VF progression in 14% of POAGTable 3
Multivariate logistic regression analysis of risk factors for glaucoma progression,
All patients (n ¼ 92)
Odds ratio beta value SE p
Age (y) 1.047 0.046 0.032 0.150
Female 1.733 0.550 0.820 0.502
Range of IOP (mmHg) 1.165 0.153 0.075 0.041
Mean IOP (mmHg) 1.083 0.080 0.161 0.619
Period of follow up (y) 0.823 0.194 0.231 0.399
No. of VF tests 1.461 0.379 0.134 0.005
Disc hemorrhage 3.823 1.341 1.079 0.214
Glaucoma family history 5.630 1.728 0.984 0.079
* Indicates statistical significance.
IOP ¼ intraocular pressure; SE ¼ standard error; VF ¼ visual field.patients with Chinese ethnicity during a mean follow-up time
of 5.4 years. The result was comparable with that of the
interim outcome of the CIGTS, a prospective study in which
Asians constitued <5% of the participants; during 5 years of
follow up, a substantial VF loss occurred in 10.7% of medi-
cally treated patients and 13.5% of surgically treated
patients.23
Reducing the IOP is beneficial for glaucoma patients to
maintain visual function, but uncertainty exists regarding
which IOP variable has the most significant impact on disease
progression for patients under treatment. We found that an
increased peak IOP was accompanied by a wide IOP range;
both findings were risk factors for VF deterioration, after
adjusting for the mean IOP and other potential risk factors;
however, the peak IOP seemed to have slightly more weight
than the IOP range. Each 1-mmHg increase in the peak IOP
increased the risk of VF progression by 23.5%, whereas each
1-mmHg increase (wider) in the IOP range increased the risk
of VF progression by 16.5% during our average follow up of
5.4 years. In a retrospective study, which enrolled 587 eyes
with a mean follow up of 6.4 years, De Moraes et al9 also
concluded that the peak IOP was a better predictor of pro-
gression than the mean IOP or fluctuation in the IOP. In
another study that assessed the association between IOP pa-
rameters and VF loss in participants of the CIGTS, Musch
et al10 found that the peak IOP, fluctuation in IOP, and the
range of the IOP were all significantly associated with worse
VF over a 3e9-year period in the medication group.
As our correlation study shows, IOP variables may interact
with each other and lead to subsequent VF deterioration,10
even when the mean IOP has been controlled at an accept-
able level.8 In clinical practice, it may take years for clinicians
to better estimate the intervisit IOP fluctuation of a particular
patient. Our results indicated that an IOP measure that is
higher than those usually obtained during follow up, once
confirmed, should not be regarded as an insignificant outlier,
but regarded as an alarm indicating suboptimal control of the
patient's diurnal or long-term IOP. Because of recent evidence
that peak circadian IOP in glaucoma patients usually occurs
during off-office hours,24,25 the expectation is that an even
higher IOP probably occurs at nighttime and strict control of
the IOP is required.including and excluding patients with cataract extraction: Model 1.
Excluding patients with cataract extraction (n ¼ 84)
Odds ratio beta value SE p
1.056 0.054 0.032 0.090
2.505 0.918 0.909 0.312
* 1.172 0.159 0.076 0.035 *
1.056 0.055 0.166 0.742
0.831 0.186 0.237 0.434
* 1.517 0.417 0.145 0.004 *
2.995 1.097 1.094 0.316
4.711 1.550 0.987 0.117
Table 4
Multivariate logistic regression analysis of risk factors for glaucoma progression, including and excluding patients with cataract extraction: Model 2.
All patients (n ¼ 92) Excluding patients with cataract extraction (n ¼ 84)
Odds ratio beta value SE p Odds ratio beta value SE p
Age (y) 1.048 0.047 0.032 0.144 1.056 0.054 0.032 0.090
Female 1.794 0.584 0.830 0.481 2.383 0.868 0.906 0.338
Peak IOP (mmHg) 1.235 0.211 4.222 0.044 * 1.236 0.212 0.105 0.044 *
Mean IOP (mmHg) 0.896 0.110 0.206 0.593 0.879 0.130 0.211 0.539
Period of follow up (y) 0.802 0.221 0.229 0.335 0.802 0.221 0.235 0.347
No. of VF tests 1.500 0.405 0.136 0.003 * 1.557 0.443 0.148 0.003 *
Disc hemorrhage 3.958 1.376 1.084 0.205 3.113 1.136 1.099 0.302
Glaucoma family history 5.994 1.791 0.986 0.069 5.063 1.622 0.986 0.100
* Indicates statistical significance.
IOP ¼ intraocular pressure; SE ¼ standard error; VF ¼ visual field.
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parameter associated with VF progression, which is in line
with the findings of the AGIS.8 Our study was retrospective
and VF tests were not performed at a scheduled interval;
however, as part of our clinical strategy, we routinely per-
formed three to four tests during the first year of follow up to
identify patients with rapid progression. In the real world,
clinicians tend to repeat VF tests within a shorter interval
when they are managing patients with more advanced glau-
coma or with a VF defect that is threatening central vision,
even before VF progression has been detected. In our study,
the average MD and the percentage of eyes with central VF
involvement at baseline were not significantly different be-
tween eyes with and without VF progression. A greater
number of VF tests in our patients with progression, compared
to the number of VF tests in patients without progression, were
likely to be associated with a clinical judgment of possible
disease progression in the first place. To improve the detection
of early VF progression in glaucoma, the preferred practice
pattern recommends repeating VF testing sooner than glau-
coma patients with regular follow-up and regular VF exami-
nations when likely progression is detected.26
We did not find a correlation between the spherical equivalent
or axial length and VF progression by using logistic or linear
regression analysis. However, myopia was a risk factor of glau-
coma formation. The findings are coherent with several studies
that found that neither axial length nor myopia was associated
with VF progression in open-angle glaucoma.3,8,18 By contrast,
Chihara et al11 found that glaucomatous eyes with high myopia
(average spherical equivalent, e9.3 D) were at high risk of VF
progression, and Lee et al12 found that POAG patients with
myopia greater than 6.0 D had greater VF exacerbation. We
compared our study with Lee's work, and adopted different
criteria to define progression in Chinese patients with POAG.We
found that our population was older (58.0 ± 15.5 years vs.
48.6± 14.2 years), less myopic (3.1± 4.4 D vs.e5.1± 4.2 D),
had worse initial MD (8.9 ± 5.9 dB vs. e5.0 ± 4.5 dB), and
lower mean IOP during follow up (14.5 ± 2.6 mmHg vs.
15.9±2.9mmHg).These differencesmayhave contributed to the
disparity in results between our study and Lee's work. Based on
these paradoxical results, whether myopia is a risk factor for
glaucomatous VF progression awaits further study forclarification. In light of existing literature and our findings, the
role ofmyopia inVFprogression canbeovercome, at least inpart,
by aggressive IOP reduction.
Our study is limited by its small sample size, relatively short-
term follow up, and shortcomings inherent in retrospective
studies. The various follow-up periods and inconsistent intervals
between VF tests may have prohibited us from detecting pro-
gression in some patients. However, our inclusion criteria of five
ormore qualified tests over aminimumspan of 2 yearsmakes this
occurrence less likely. Another issue that may be argued is that a
postintervention low IOP may contribute to the IOP variation,
which in fact results from the intervention rather than leads to
progression. To minimize the impact of IOP variation after
glaucoma surgical intervention in our study results, we excluded
the early postintervention IOP from our analysis. The findings
that peak IOP is a significant factor associated with VF pro-
gression and that it is highly correlated with IOP fluctuation and
the range of IOP indicate that the variation in IOP leading to
disease progression is a more likely explanation. The patients
with high myopia may have been too few in number (n ¼ 24,
26%) in this study to detect a correlation betweenVF progression
andmyopic refraction, although refractive error is onlyone aspect
of disease presentation in myopia.
In conclusion, we found the proportion of eyes reaching the
progression endpoint after a mean follow up of 5.4 years was
quite similar to that reported in the CIGTS after 5 years of
follow up. Eyes with a greater number of VF tests, an
increased peak IOP, and a wide range in IOP were more likely
to have VF progression, based on the CIGTS criteria, in this
cohort of Chinese patients with POAG.
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